Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of lanreotide versus placebo for palliative treatment of malignant small bowel obstruction due to peritoneal carcinomatosis
2005-002349-38Phase 3Completed
- Sponsor
- Ipsen
- Start
- Dec 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bowel obstruction and peritoneal carcinomatosis (PC) comparing Lanreotide 30 mg with Placebo (2 arms). Primary endpoint: Primary: Percentage of responder patients at Day 7. Started Dec 2006; status: completed.
02
Drugs
lanreotide
03
Conditions
bowel obstructionperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2005-002349-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002349-38.